Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04925934 · ClinicalTrials.gov registry record · Phase 2

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

A Phase 2 study of Lupus Erythematosus, Systemic, sponsored by Amgen.

Completed
Registry status
Phase 2
Development phase
214
Enrollment target
20
Study locations

NCT04925934 is a Phase 2 study of Lupus Erythematosus, Systemic that has completed, run by Amgen. The registered enrollment target is 214 participants, roughly in line with the 196-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04925934, a Phase 2 study of Lupus Erythematosus, Systemic, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 2
Development phase
214 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in approximately 195 participants. The study duration will be 48 weeks, with a safety follow-up through week 56.There will be 3 parallel arms - 2 active treatment and 1 placebo.

Conditions Studied

Lupus Erythematosus, Systemic

Interventions

  • OTHER Placebo
  • DRUG VIB7734

Study Locations (20)

Florida

  • Clinical Research of West Florida Inc - Clearwater - Clearwater
  • Millennium Research - Ormond Beach
  • IRIS Research and Development LLC - Plantation
  • Clinical Research of West Florida Inc - Tampa - Tampa

Texas

  • Tekton Research Inc - Austin
  • Precision Comprehensive Clinical Research Solutions - Colleyville
  • Metroplex Clinical Research Center - Dallas
  • Southwest Rheumatology Research, LLC - Mesquite

New York

  • NYU Langone Ambulatory Care Brooklyn Heights - Brooklyn
  • Feinstein Institute For Medical Research - Manhasset
  • SUNY Upstate Medical Center - Syracuse

Buenos Aires

  • Consultorios Médicos Dr. Doreski - Ciudad Autónoma de Buenos Aires
  • Clínica Adventista Belgrano - Estomba
  • Framingham Centro Médico - La Plata

California

  • Inland Rheumatology Clinical Trials Incorporated - Upland

Georgia

  • Emory University School of Medicine - Atlanta

Kentucky

  • Bluegrass Community Research Inc - Lexington

North Carolina

  • DJL Clinical Research - Charlotte

Trial Details

FieldValue
Enrollment Target 214 participants
Start Date 2021-05-28
Est. Completion 2023-06-09
Phase Phase 2

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04925934

The ClinicalTrials.gov registry entry for NCT04925934 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 196-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04925934 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Texas, New York.

Frequently Asked Questions

What is clinical trial NCT04925934 about?

NCT04925934 is a clinical study titled "Study of VIB7734 for the Treatment of Moderate to Severely Active SLE". A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in approximately 195 participants. The study duration will be 48 weeks, with a safety follow-up through week 56.There will be 3 pa...

What is the current status of trial NCT04925934?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2021-05-28. Estimated completion is 2023-06-09.

What conditions does trial NCT04925934 study?

This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.

What interventions are being tested in trial NCT04925934?

The interventions under investigation include: Placebo (OTHER), VIB7734 (DRUG).

Who is sponsoring clinical trial NCT04925934?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04925934 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus Erythematosus, Systemic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lupus Erythematosus, Systemic

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.